biostudies-literatureUnknown9(1)Ramakrishna PDr. Reddy&apos;s Laboratories<h4>Background</h4>Fondaparinux is the first approved anticoagulant drug among factor Xa inhibitors, with proven effectiveness and safety in preventing deep vein thrombosis. However, limited data are available supporting the benefit-risk profile of fondaparinux vs enoxaparin in a real-world group of Indian patients with deep vein thrombosis.<h4>Objective</h4>To compare the effectiveness and tolerability of fondaparinux vs enoxaparin in patients with symptomatic deep vein thrombosis in a long-term real-world setting.<h4>Methods</h4>Data from the electronic medical records of adult patients diagnosed with deep vein thrombosis prescribed fondaparinux (n = 503) or enoxaparin (n = 508) as monotherapy were analyzed. Effectiveness was analyzed in terms of recurrence, duration, and type of deep veDrugs - real world outcomes109-119https://www.ebi.ac.uk/biostudies/studies/S-EPMC8844336biostudies-literatureEffectiveness and Tolerability of Fondaparinux vs Enoxaparin in a Population of Indian Patients with Symptomatic Deep Vein Thrombosis: A Retrospective Real-World Study.PMC8844336Ramakrishna PMane ARai KSubramaniyan ASahu TRajkumar MKhan MYPandit SJain MPai PGaurav KGupta PCfalseEffectiveness and Tolerability of Fondaparinux vs Enoxaparin in a Population of Indian Patients with Symptomatic Deep Vein Thrombosis: A Retrospective Real-World Study.<h4>Background</h4>Fondaparinux is the first approved anticoagulant drug among factor Xa inhibitors, with proven effectiveness and safety in preventing deep vein thrombosis. However, limited data are available supporting the benefit-risk profile of fondaparinux vs enoxaparin in a real-world group of Indian patients with deep vein thrombosis.<h4>Objective</h4>To compare the effectiveness and tolerability of fondaparinux vs enoxaparin in patients with symptomatic deep vein thrombosis in a long-term real-world setting.<h4>Methods</h4>Data from the electronic medical records of adult patients diagnosed with deep vein thrombosis prescribed fondaparinux (n = 503) or enoxaparin (n = 508) as monotherapy were analyzed. Effectiveness was analyzed in terms of recurrence, duration, and type of deep ve2022-01-01T00:00:00Z2022 Mar2025-04-04T08:41:25.177Z2024-11-13T10:36:59.512ZS-EPMC88443363443534010.1007/s40801-021-00273-4